Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz

Ali Mcbride, Sanjeev Balu, Kim Campbell, Mohan Bikkina, Karen MacDonald, Ivo Abraham

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Aim: Biosimilar medicines offer significant cost-savings potential over their reference products, which can be re-allocated to provide access to other cancer treatments on a budget-neutral basis. Methods: Simulation study using cost data for the USA under consideration of several prophylaxis patterns. Results: Potential savings from conversion from reference filgrastim to biosimilar filgrastim-sndz are significant. These savings expand budget-neutral access to novel immunotherapies (obinutuzumab; pembrolizumab) or supportive care (filgrastim-sndz). Conclusion: The combination of biosimilar savings and expanded access increases the value of cancer care as the same supportive care is provided at lower cost, additional cancer care is enabled at no additional cost, and more patients will have access to cancer care.

Original languageEnglish (US)
Pages (from-to)2285-2295
Number of pages11
JournalFuture Oncology
Volume13
Issue number25
DOIs
StatePublished - Oct 2017

Keywords

  • biosimilars
  • neutropenia
  • pharmacoeconomics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz'. Together they form a unique fingerprint.

  • Cite this